

[FULL TEXT LINKS](#)[Review](#) > [Sci Rep. 2016 May 6:25247. doi: 10.1038/srep25247.](#)

Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: A systematic review and meta-analysis

Regina Ws Sit ¹, Vincent Ch Chung ¹, Kenneth D Reeves ², David Rabago ³, Keith Kw Chan ¹,
Dicken Cc Chan ¹, Xinyin Wu ¹, Robin St Ho ¹, Samuel Ys Wong ¹

Affiliations

PMID: 27146849 PMCID: [PMC4857084](#) DOI: [10.1038/srep25247](#)

[Free PMC article](#)

Erratum in

[Erratum: Hypertonic dextrose injections \(prolotherapy\) in the treatment of symptomatic knee osteoarthritis: A systematic review and meta-analysis.](#)

Sit RW, Chung VC, Reeves KD, Rabago D, Chan KK, Chan DC, Wu X, Ho RS, Wong SY.





[Sci Rep. 2017 Apr 7;7:45879. doi: 10.1038/srep45879.](#)

PMID: 28387754 [Free PMC article](#). No abstract available.

Abstract

Hypertonic dextrose injections (prolotherapy) is an emerging treatment for symptomatic knee osteoarthritis (OA) but its efficacy is uncertain. We conducted a systematic review with meta-analysis to synthesize clinical evidence on the effect of prolotherapy for knee OA. Fifteen electronic databases were searched from their inception to September 2015. The primary outcome of interest was score change on the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Three randomized controlled trials (RCTs) of moderate risk of bias and one quasi-randomized trial were included, with data from a total of 258 patients. In the meta-analysis of two eligible studies, prolotherapy is superior to exercise alone by a standardized mean difference (SMD) of 0.81 (95% CI: 0.18 to 1.45, p = 0.012), 0.78 (95% CI: 0.25 to 1.30, p = 0.001) and 0.62 (95% CI: 0.04 to 1.20, p = 0.035) on the WOMAC composite scale; and WOMAC function and pain subscale scores respectively. Moderate heterogeneity exists in all cases. Overall, prolotherapy conferred a positive and significant beneficial effect in the treatment of knee OA. Adequately powered, longer-term trials with uniform end points are needed to better elucidate the efficacy of prolotherapy.

Figures



Related information

[MedGen](#)

LinkOut – more resources

Full Text Sources

[Europe PubMed Central](#)
[Nature Publishing Group](#)
[PubMed Central](#)

Other Literature Sources

[scite Smart Citations](#)
[Medical](#)
[ClinicalTrials.gov](#)